Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) Short Interest Update

Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) was the target of a large decline in short interest in July. As of July 15th, there was short interest totalling 1,900,000 shares, a decline of 15.2% from the June 30th total of 2,240,000 shares. Based on an average trading volume of 950,400 shares, the days-to-cover ratio is currently 2.0 days.

Matinas BioPharma Stock Performance

Shares of NYSEAMERICAN:MTNB opened at $0.17 on Tuesday. The company has a market cap of $41.39 million, a PE ratio of -1.38 and a beta of 1.70. Matinas BioPharma has a 12 month low of $0.11 and a 12 month high of $0.89.

Matinas BioPharma (NYSEAMERICAN:MTNB) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.03) EPS for the quarter.

Institutional Investors Weigh In On Matinas BioPharma

Institutional investors and hedge funds have recently bought and sold shares of the stock. Private Advisor Group LLC lifted its stake in Matinas BioPharma by 31.1% in the 4th quarter. Private Advisor Group LLC now owns 337,330 shares of the company’s stock valued at $73,000 after buying an additional 80,000 shares in the last quarter. Alliance Wealth Management Group purchased a new stake in Matinas BioPharma in the 2nd quarter valued at approximately $299,000. Finally, Arkadios Wealth Advisors lifted its stake in Matinas BioPharma by 16.1% in the 4th quarter. Arkadios Wealth Advisors now owns 1,624,000 shares of the company’s stock valued at $351,000 after buying an additional 225,000 shares in the last quarter. Hedge funds and other institutional investors own 11.77% of the company’s stock.

Matinas BioPharma Company Profile

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.